Abciximab Drug info with Brand name and Price
- Therapeutic Classification:antiplatelet agents
- Pharmacologic Classification:glycoprotein iib iiia inhibitors
- Platelet Glycoprotein IIb/IIIa Receptor Antagonist
- SCHEDULE: H
- Category C
- STORAGE: Refrigerate at 2-8’C. Do not freeze.
- STABILlSATION IN PATIENTS WLJH UNSTABLE ANGINA: Adult: 250 , mcglkg body weight bolus injection over 1 min followed by 0.125 mcglkg body weight/min infusion, started up to 24 hrs before and 12 hrs after the possible intervention. Max Dose: 10 mcg/min infusion.
- ADJUNCT FOR THE PREVENTION OF ACUTE ISCHAEMIC COMPLICATIONS IN PERCUTANEOUS TRANSLUMINAL CORONARY PROCEDURES: Adult: 250 mcglkg body weight bolus injection over 1 min followed by 0.125 mcg/kg body weight/min infusion. Max Dose: 10 mcglmin infusion.
Contraindicated of Abciximab in:
- Hypersensitivity to abciximab or murine (mouse) protein.
- Active internal bleeding.
- Recent significant GI or GU bleeding (within 6 wk).
- History of CVA (within 2 yr) or CVA with neurologic sequelae.
- History of bleeding disorder.
- Recent (within 7 days) oral anticoagulant therapy (PT 1.2 times control).
- Platelet count <100,000 cells/mm³.
- Recent trauma or major surgery (within 6 wk).
- Intracranial neoplasm.
- Aneurysm or AV malformation.
- Severe uncontrolled hypertension.
- History of vasculitis.
- Concurrent use of another parenteral GP IIb/IIIa inhibitor.
- Recent or concurrent dextran therapy.
- Cl: Hypersensitivity to any component or to murine proteins; active bleeding; patients at increased risk of haemorrhage, recent (within 6 weeks) GI or genitourinary bleeding of clinical
- significance; history of cerebrovascular accident (CV A) within 2 yrs or CVA with a significant residual neurological deficit; bleeding diathesis; thrombocytopaenia (10,000 cells/microlitre); clotting abnormalities; administration of oral anticoagulants within 7 days; recent (within 6 weeks) major surgery or trauma; intracranial turner, arteriovenous malformation or aneurysm; severe uncontrolled hypertension; severe renal or hepatic impairment presumed or documented history of vasculitis; use of IV dextran before PTCA, or intent of use during PCTA.
- SP: Elderly >65 yrs, recent thrombolytic therapy, unsuccessful PTCA. During readministration; use with thrombolytics, anticoagulants and other antiplatelet agents; while obtaining IV route and/or during arterial and venous punctureslintubations; measure platelet count, prothrombin time and APTT to identify preexisting haemostatic abnormalities, before administration; pregnancy and lactation: childn; patients weighing <75 kg.
Use Abciximab Cautiously in:
- Patients weighing <75 kg or >65 yr (increased risk of bleeding).
- History of previous GI pathology.
- Concurrent thrombolytic or heparin therapy.
- PCI within 12 hr of onset of MI symptoms or PCI procedure lasting >70 min.
- OB: Lactation: Pedi: Safety not established.
- Used with heparin and aspirin to decrease cardiac ischemic complications before or after percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA).
- In combination with heparin and and/or low-dose alteplase or reteplase to enhance coronary perfusion in patients with acute coronary syndromes (ACS).
Adv. Reactions/Side Effects of Abciximab
- CNS: abnormal thinking, dizziness , headache.
- CV: hypotension, atrial fibrillation/flutter , bradycardia, complete AV block, supraventricular tachycardia, vascular disorder, chest pain, peripheral edema.
- Hemat: bleeding, thrombocytopenia .
- Injection: 2 mg/ml in 5-ml vials
Abciximab Brand name and Price —
- REOPRO Eli Lilly VIAL 2mg/mL 10mg Price Rs- 19740.00